CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Addus HomeCare Q3 adjusted EPS beats estimates; to acquire AccentCare personal care division

By Reuters News


Overview

  • U.S. home care provider's Q3 service revenue rose 7% yr/yr

  • Q3 adjusted EPS rose 17% and beat analyst expectations

  • Company to acquire AccentCare personal care division, expanding revenue base by nearly 19%


Outlook

  • Company expects to close and integrate AccentCare personal care acquisition in coming quarters

  • Addus plans to pursue further acquisitions to expand market density and operational scale

  • Company anticipates continued profitable growth through end of 2026


Result Drivers

  • PERSONAL CARE GROWTH - Co said personal care services drove Q3 growth, aided by organic volume expansion, acquisition contribution and favorable rate adjustments

  • HOSPICE SEGMENT - Hospice segment saw higher average daily census and organic revenue growth, excluding prior year price concession effects

  • HOME HEALTH RECOVERY - Home health segment showed improved admission and volume trends, returning to organic revenue growth


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Adjusted EPS

Beat

$1.83

$1.80 (14 Analysts)

Q3 Net Income

$28.60 mln

Q3 Adjusted EBITDA

Beat

$51.20 mln

$50.29 mln (13 Analysts)

Q3 Operating Cash Flow

$40.90 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy"

  • Wall Street's median 12-month price target for Addus Homecare Corp is $137.00, about 8.9% above its November 2 closing price of $125.75

  • The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 16 three months ago


Reuters Recommended Reads

  • Nov 2 - Diversified Healthcare Trust Q3 net loss narrows amid occupancy growth

  • Nov 3 - AdaptHealth posts Q3 loss due to goodwill impairment charge

  • Nov 3 - Syra Health Q3 revenue jumps to record high on workforce contracts


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.